An OCT-Guided Variable Dosing Regimen With Ranibizumab for the Treatment of Neovascular AMD

Part of paid clinical trials in Miami, Florida.

Sponsor
University of Miami
Study ID
NCT00373659
Phase
PHASE2
Status
Completed

Conditions

  • Neovascular Age-related Macular Degeneration

Eligibility Criteria

Sex
ALL
Age
50 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This study was designed to evaluate a variable dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD) in the Prospective OCT Imaging of Patients with Neovascular AMD Treated with Intra-Ocular Ranibizumab (PrONTO) study.

Key Dates

First listed
Sep 8, 2006
Start date
Aug 31, 2004
Status verified
Jun 2012
Primary completion
Jun 30, 2007
Completion
Jun 30, 2007

Study Design

Enrollment
40 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Change in visual acuity vs baseline

Locations (1)

FacilityCityStateZIPSite coordinators
Bascom Palmer Eye InstiyuteMiamiFlorida33136-

Find similar trials in Miami, FL

By research site
Bascom Palmer Eye Instiyute· Miami, FL

Related Studies